news
Molecule in body that blocks antibody binding to SARS-CoV-2 discovered
Biliverdin attaches to a region of the SARS-CoV-2 Spike protein, stabilising it so that it is not able to expose its structure to antibodies, a new study has shown.
List view / Grid view
Covid-19
news
SARS-CoV-2 infection induces polyfunctional antibodies, study finds
Using newly developed assays, researchers have characterised the antibody response of individuals infected with SARS-CoV-2.
news
Novel COVID-19 vaccine could offer broad protection from coronaviruses
A new COVID-19 vaccine could provide protection from severe infection from a range of coronaviruses, studies in pigs have shown.
news
MK-4482 antiviral effective against SARS-CoV-2 in hamster study
The drug MK-4482 decreased viral levels in the lungs of hamsters treated for SARS-CoV-2 infection, researchers have shown.
article
Exploring the connection between COVID-19 and diabetes
Dr Brittany Busse discusses why COVID-19 can influence the onset of diabetes and how this could shape the development of therapeutics.
news
Fragment screening used to identify potential SARS-CoV-2 antivirals
Researchers have used fragment screening alongside computational docking to reveal 20 hit antiviral compounds against SARS-CoV-2.
news
Stem cell-derived organoids developed to test SARS-CoV-2 drugs on gut
Induced pluripotent stem cells (iPSC) intestinal organoids have been created to duplicate SARS-CoV-2, enabling drug testing.
article
COVID-19, broad-spectrum therapeutics and the magic blanket paradigm
Dr Praveen Prathapan explains why broad-spectrum therapeutics need to be identified to provide a safety net against pandemics, including COVID-19.
news
Spikes from AstraZeneca COVID-19 vaccine resemble SARS-CoV-2 S proteins
Using cryo-electron microscopy, researchers have shown that the Spike (S) protein on cells exposed to the AstraZeneca vaccine is highly similar to the SARS-CoV-2 S protein.
news
Dynamic model of SARS-CoV-2 S protein reveals vaccine targets
A model of the SARS-CoV-2 Spike protein surface has uncovered vulnerabilities that researchers say could inform the development of COVID-19 vaccines.
news
X-ray screening reveals two promising SARS-CoV-2 drug candidates
Using a high-brilliance X-ray lightsource and protein crystallography, researchers have identified two drugs that inhibit the main protease of SARS-CoV-2.
article
Developing a broadly neutralising antibody therapeutic to combat SARS-CoV-2
With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe…
article
The development of biomaterial-based vaccine platforms against viruses
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
article
Drug Target Review Antibodies ebook 2021
Within this ebook, find articles on how a lead bNAb candidate was identified to combat COVID-19 and why antibodies could present the answer to HIV treatment and vaccines.
news
Inexpensive drug protects against COVID-19 inflammation in pre-clinical trials
A drug called topotecan (TPT) was administered to mice up to four days after COVID-19 infection, reducing inflammation and morbidity.
